Skip to content

The comparison of vancomycin and teicoplanin in treatment of hospitalized children with severe pneumonia

The comparison of efficacy and safety of vancomycin and teicoplanin in hospitalized children with severe pneumonia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015030111145N13
Enrollment
100
Registered
2015-03-16
Start date
2015-03-16
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia. Pneumonia, unspecified

Interventions

Intervention 1: Intervention group 1: Intravenous infusion of vancomycin 10 mg/kg every 6 hours. Intervention 2: Intervention group 2: Intravenous infusion of teicoplanin 10 mg/kg daily.
Treatment - Drugs
Intervention group 1: Intravenous infusion of vancomycin 10 mg/kg every 6 hours
Intervention group 2: Intravenous infusion of teicoplanin 10 mg/kg daily

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Months to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: children 2 months to 12 years old hospitalized in Pediatrics Intensive Care Unit of Kashan Beheshti Hospital; fever (axillary temperature 37.5° C or more); tachypnea; respiratory distress. Exclusion criteria: the history of pulmonary disease including asthma; documented heart disease or other chronic disease; renal disease; immunodeficiency; malnutrition or growth failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fever improvement. Timepoint: Every 6 hours. Method of measurement: Mercury thermometer with axillary method.;Tachypnea improvement. Timepoint: Daily. Method of measurement: Breathing rate.;Improvment of respiratory distress. Timepoint: Daily. Method of measurement: Observed breathing.

Secondary

MeasureTime frame
Renal failure. Timepoint: Daily. Method of measurement: creatinin measurement (milligram/deciliter).;Red man syndrome. Timepoint: During injection. Method of measurement: Observed by nurse.;Duration of hospital stay. Timepoint: At discharge. Method of measurement: Days recorded in dossier.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Reza Sharif

Kashan University of Medical Sciences

mrsharifmd@yahoo.com+98 31 5554 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026